Department of Pharmacy Services, HonorHealth - John C. Lincoln Medical Center, 250 E. Dunlap, Ave, Phoenix, AZ 85020, United States.
Department of Pharmacy Practice, Midwestern University, College of Pharmacy-Glendale, 19555 N 59th Avenue, Glendale, AZ 85308, United States.
J Crit Care. 2019 Apr;50:50-53. doi: 10.1016/j.jcrc.2018.11.010. Epub 2018 Nov 14.
To compare the efficacy and safety of lacosamide versus phenytoin for seizure prophylaxis following TBI.
All TBI patients who received prophylaxis with either phenytoin or lacosamide were retrospectively identified. The incidence of seizures within the first 7 days of injury were compared along with adverse effects requiring drug discontinuation. A planned sub-group analysis was performed for patients with severe TBI (GCS < 9).
There were 481 patients (phenytoin, n = 116; lacosamide, n = 365). Demographics were similar but age (50 ± 21 vs 58 ± 22 years, P < .001) and initial GCS (11.3 ± 4.3 vs 12.5 ± 3.8, P = .010) were lower in the phenytoin group. The need for mechanical ventilation was higher (53% vs 38%, P = .004). Seizures occurred in 0.9% of the phenytoin group and 1.4% of the lacosamide group (P = 1.00). ADEs were significantly higher with phenytoin (5.2% vs 0.5%, P = .003). This difference remained significant upon multivariate analysis [OR(95% CI) = 9.4(1.8-48.9)]. Subgroup analysis for patients with severe TBI revealed no difference in seizures (phenytoin, 0% vs lacosamide, 1.5%; P = 1.00) but more ADEs with phenytoin (12.5% vs 0%, P = .010).
There was no difference between lacosamide and phenytoin in the prevention of early post traumatic seizures in patients following TBI. Lacosamide may have a more tolerable side effect profile.
比较左乙拉西坦与苯妥英预防 TBI 后癫痫发作的疗效和安全性。
回顾性识别所有接受苯妥英或左乙拉西坦预防治疗的 TBI 患者。比较伤后 7 天内的癫痫发作发生率及需要停药的不良反应。对 GCS<9 的重度 TBI 患者进行了计划的亚组分析。
共有 481 例患者(苯妥英组,n=116;左乙拉西坦组,n=365)。两组患者的人口统计学特征相似,但苯妥英组的年龄(50±21 岁 vs 58±22 岁,P<0.001)和初始 GCS(11.3±4.3 分 vs 12.5±3.8 分,P=0.010)较低。需要机械通气的患者比例较高(53% vs 38%,P=0.004)。苯妥英组癫痫发作发生率为 0.9%,左乙拉西坦组为 1.4%(P=1.00)。苯妥英组 ADE 发生率明显更高(5.2% vs 0.5%,P=0.003)。多变量分析显示,这种差异仍然具有统计学意义[OR(95%CI)=9.4(1.8-48.9)]。对于重度 TBI 患者的亚组分析显示,两组癫痫发作无差异(苯妥英组,0% vs 左乙拉西坦组,1.5%;P=1.00),但苯妥英组 ADE 更多(12.5% vs 0%,P=0.010)。
在 TBI 后患者中,左乙拉西坦与苯妥英预防早期创伤后癫痫发作无差异。左乙拉西坦可能具有更可耐受的不良反应谱。